Podcast
Medical News Podcast
Hosted by PeerDirect · EN
The Medical News Podcast by PeerDirect delivers news and interviews with clinical thought leaders and researchers to keep you informed of the latest breakthroughs, guidelines, and insights in your specialty. Designed for clinicians with stories selected by the PeerDirect editorial board. Visit us at peerdirect.com to sign-up for our newsletter.
60episodes
Episodes
Newest firstAll episodes
Can we actually slow the progression of type 1 diabetes after diagnosis?
4d ago00:04:40Tap to summarizeThis episode of the PeerDirect Medical News Podcast highlights three major developments shaping diabetes and hematologic oncology care. First, the FDA expanded approval of teplizumab for selected children and adolescents with newly diagnosed Stage 3 type 1 diabetes, making it the first therapy to modify disease progression after diagnosis by preserving beta-cell function. Additional stories review evidence supporting continuous glucose monitoring in basal insulin-treated type 2 diabetes and promising Phase III data showing talquetamab-based bispecific antibody regimens improve outcomes in relapsed or refractory multiple myeloma.
Transcribe →Revisiting Atopic March in the Era of Type 2 Inflammation
1w ago00:13:52Tap to summarizeDrs. Gupta and Newhall discuss how the traditional idea of the atopic march—eczema progressing to food allergy, asthma, and allergic rhinitis—may be too simplistic and does not always match what they see in the clinic, given what is now known about shared type 2 inflammation, cytokine pathways, and barrier dysfunction across organs. They note that these allergic conditions often arise in parallel rather than in sequence. They suggest using the atopic march as a way to talk about risk, while focusing on early skin protection, timely food allergen introduction, and emerging biologic treatments like dupilumab to potentially reshape a child’s long-term allergic trajectory.
Transcribe →Can one kidney drug expand treatment to millions more patients?
2w ago00:04:52Tap to summarizeThis episode of the PeerDirect Medical News Podcast reviews three developments with potential implications across nephrology, oncology, and public health. Highlights include the FIND-CKD trial showing finerenone may slow disease progression in chronic kidney disease patients without diabetes, seven-year CROWN trial data demonstrating durable long-term disease control with lorlatinib in advanced ALK-positive lung cancer, and a JAMA Network Open study linking measles-related vitamin A misinformation to increased toxic exposures. Together, these findings underscore evolving treatment paradigms and the growing impact of health communication on patient outcomes.
Transcribe →Early Diagnosis: Screening for ATTR-CM in HFpEF and Aortic Stenosis Populations
2w ago00:11:51Tap to summarizeDrs. Dasgupta and Sarswat review how ATTR cardiomyopathy remains under-recognized despite its prevalence in older patients with heart failure, emphasizing clinical red flags across cardiac and systemic manifestations. They outline a practical diagnostic pathway that prioritizes early identification using light-chain evaluation, bone scintigraphy, and genetic testing to distinguish transthyretin subtypes and initiate timely, disease-modifying therapy.
Transcribe →Highlights From ISC 2026: Uncontrolled Hypertension Among Stroke Survivors, PFO Guidelines Updates, and Clinical Trial Participation Benefit
3w ago00:11:21Tap to summarizeDrs. Saver and Sanossian discuss ISC 2026 data highlighting neurologists’ frequent inaction on markedly uncontrolled hypertension in high‑risk stroke patients and the need for specialists to “own” blood pressure management at every visit. They also review refinements in patent foramen ovale (PFO) risk stratification, including Pascal algorithm-defined “possible” PFO cases, and explore how a “clinical trial effect” may lower stroke risk through greater patient engagement.
Transcribe →Recognizing Cardiovascular Risk in Patients With Lupus Nephritis
3w ago00:07:50Tap to summarizeDrs. McMahon and Kalunian discuss how patients with lupus nephritis face a markedly higher risk of cardiovascular disease and how traditional risk calculators fail to capture the added danger from chronic inflammation, steroids, and disease-specific factors. They call for a paradigm shift toward aggressive, early, and continuous cardiovascular protection—including tighter blood pressure targets, earlier statin use, lifelong hydroxychloroquine when possible, and close multidisciplinary management from the time of diagnosis.
Transcribe →Could the current Ebola outbreak expose cracks in global public health?
3w ago00:05:21Tap to summarizeThis episode of the PeerDirect Medical News Podcast examines the rapidly expanding Ebola outbreak in Congo and concerns over weakening global public health infrastructure, reviews new Phase III obesity data showing substantial weight loss with Lilly’s triple-agonist retatrutide, and highlights promising ASCO 2026 lung cancer data for a TROP2-directed ADC combined with pembrolizumab in frontline NSCLC.
Transcribe →AI, Machine Learning, and HRCT in ILD: Challenges and Future Opportunities
3w ago00:11:31Tap to summarizeDrs. Humphries and Swigris describe how AI-driven CT analysis can detect subtle imaging features of ILD and UIP, outperforming visual reads for risk stratification and prognosis. They highlight how these tools may enable earlier identification of patients at high risk for fibrosis progression while also stressing current limitations, including opacity of algorithms, data dependence, and the need to adapt imaging hardware and clinical workflows.
Transcribe →How Long Is Too Long? Maintenance Therapy for Patients With Lupus Nephritis
4w ago00:09:12Tap to summarizeDrs. McMahon and Kalunian discuss how the latest lupus nephritis guidelines from the American College of Rheumatology and European Alliance of Associations for Rheumatology are shifting care from short-term, reactive treatment to longer-term, continuous maintenance—often 3 to 5 years or more—to better prevent kidney flares and preserve renal function. They highlight emerging data on biologic-based triple therapy (including belimumab); the importance of biomarkers and repeat biopsies; and the growing push toward personalized, sometimes indefinite, therapy for high‑risk patients.
Transcribe →Facial Pain, Migraine, and the Trigeminal System
4w ago00:12:24Tap to summarizeDrs. Chandwani and Kuruvilla explain that migraine and facial pain often share trigeminal system mechanisms, leading to frequent misdiagnosis as dental, musculoskeletal, or sinus problems, possibly resulting in unnecessary procedures. The speakers emphasize CGRP-targeted therapies, careful mechanism-based diagnosis, and multidisciplinary collaboration across neurology, orofacial pain, physical therapy, and behavioral health to improve outcomes for patients with complex facial pain and migraine presentations.
Transcribe →